The US Food and Drug Administration (FDA) on Wednesday launched a SARS-CoV-2 reference panel in aid of commercial and laboratory developers who are interacting with the agency through its pre-emergency use authorization (EUA) process.
SARS-CoV-2 is the virus that causes COVID-19.
The agency explained that reference panels help ensure the quality of tests, validation of new assays, test calibration, and monitoring of assay performance. The FDA's reference panel is an independent performance validation step for diagnostic tests of SARS-CoV-2 infection that are being used for clinical, not research, purposes.
Nucleic acid tests identify infection by confirming the presence of a virus' genetic material (RNA) and the FDA-supplied reference panel provides developers access to this material. These types of reference panels have proven to be an invaluable resource in the development of accurate, reliable and validated diagnostic tests for detecting infectious diseases.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study